国家: 以色列
语言: 英文
来源: Ministry of Health
NIVOLUMAB; RELATLIMAB
BRISTOL, MYERS SQUIBB (ISRAEL) LIMITED, ISRAEL
L01XC17
CONCENTRATE FOR SOLUTION FOR INFUSION
RELATLIMAB 4 MG/ML; NIVOLUMAB 12 MG/ML
I.V
Required
BRISTOL-MYERS SQUIBB COMPANY, USA
NIVOLUMAB
Opdualag is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.
2023-02-07
תילגנאב לפוטמל סיטרכ PATIENT CARD גלאודפוא )באמילטלרו באמולובינ( PATIENT CARD INFORMATION FOR PATIENTS Please keep this card with you at all times. Show it to any healthcare professionals treating you (e.g. doctor, nurse, pharmacist, emergency department personnel) and inform them that you are receiving treatment with Opdualag. IMPORTANT Opdualag can cause serious immune-related side effects that can affect different parts of the body. These side effects can occur at any time, may be delayed and may occur weeks to months after your last dose of treatment. Some of the following side effects can be life threatening and need to be addressed immediately: POSSIBLE SIDE EFFECTS BODY PART New or worsening cough, shortness of breath, breathing difficulties or chest pain. Lung Diarrhoea (watery, loose or soft stools) or more frequent bowel movements than usual; stools that are black, tarry, sticky or have blood or mucus; stomach area (abdomen) pain or tenderness. Stomach and bowel (gut) Yellowing of the skin or the whites of the eyes (jaundice), nausea or vomiting, pain in the right side of stomach area (abdomen), dark urine, tiredness, bleeding or bruising more easily than usual. Liver Headaches, increased sweating, weight gain or loss, fatigue (extreme tiredness), increased hunger or thirst, needing to urinate more often, hair loss, feeling cold, constipation, changes in voice, dizziness or fainting, changes in mood or behaviour, sensitivity to light, eye problems, rapid heartbeat, having difficulty thinking clearly, breath that smells sweet or fruity, a sweet or metallic taste in your mouth, a different odour to your urine or sweat, feeling sick or being sick, stomach (abdomen) pain, and deep or fast breathing. Hormone glands (including diabetes and diabetic ketoacidosis) Decrease in amount of urine, swelling in the ankles, loss of appetite or blood in urine. Kidneys Rash, itching, blistering or peeling skin; painful sores or ulcers in the mouth. Skin New or worsening chest p 阅读完整的文件
1 Opdualag_API_Feb2023_Corr_Feb2023 1. NAME OF THE MEDICINAL PRODUCT Opdualag Concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of concentrate for solution for infusion contains 12 mg of nivolumab and 4 mg of relatlimab. One vial of 20 mL contains 240 mg of nivolumab and 80 mg of relatlimab. Nivolumab and relatlimab are human immunoglobulin G4 (IgG4) monoclonal antibodies produced in Chinese Hamster Ovary cells by recombinant DNA technology. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Concentrate for solution for infusion (sterile concentrate). Clear to opalescent, colourless to slightly yellow liquid that is essentially free of visible particles. The solution has a pH of approximately 5.8 and an osmolality of approximately 310 mOsm/kg. 4. CLINICAL PARTICULARS PATIENT SAFETY INFORMATION CARD The marketing of Opdualag is subject to risk management plan (RMP) including a ‘Patient safety information card’. The Patient Safety Information Card emphasizes important safety information that the patient should be aware of before and during treatment. Please explain to the patient the need to review the card before starting treatment. 4.1 THERAPEUTIC INDICATIONS Opdualag is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment must be initiated and supervised by physicians experienced in the treatment of cancer. Posology The recommended dose for adults and pediatric patients 12 years of age and older is 480 mg nivolumab and 160 mg relatlimab every 4 weeks administered as an intravenous infusion over 30 minutes. This dose is established for pediatric patients 12 years of age and older weighing at least 30 kg (see section 5.2). Treatment with Opdualag should be continued as long as clinical benefit is observed or until treatment is no longer tolerated by the patient. Dose escalation or reduction is not recommended. Dosing delay or 阅读完整的文件